<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Maintenance of general anesthesia: Overview</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Maintenance of general anesthesia: Overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Maintenance of general anesthesia: Overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah M Khorsand, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Girish P Joshi, MB, BS, MD, FFARCSI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3504916402"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immediately after induction of general anesthesia, additional agents are necessary to maintain the anesthetic state since most induction agents have a brief duration of action. This topic will discuss use of inhalation and intravenous (IV) agents during the maintenance phase of general anesthesia.</p><p>Induction of general anesthesia is discussed in separate topics. (See  <a class="medical medical_review" href="/d/html/94135.html" rel="external">"Induction of general anesthesia: Overview"</a> and  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents"</a>.)</p><p>Emergence from general anesthesia is also discussed separately. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia"</a>.)</p><p class="headingAnchor" id="H635536908"><span class="h1">ANESTHETIC GOALS</span></p><p class="headingAnchor" id="H2864235058"><span class="h2">Overall goals</span><span class="headingEndMark"> — </span>The overall goals of the maintenance phase of a general anesthetic are to maintain Stage III surgical anesthesia (ie, unconsciousness, amnesia, immobility, unresponsive to surgical stimulation  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 1</a>)) at a safe anesthetic depth while also maintaining respiratory and hemodynamic stability. Standard monitors placed prior to induction of anesthesia are closely observed during anesthetic delivery in order to rapidly detect and correct hemodynamic, respiratory, or temperature derangements (see  <a class="medical medical_review" href="/d/html/100067.html" rel="external">"Basic patient monitoring during anesthesia"</a>). In addition, end-tidal inhalation anesthetic concentration (ETAC), raw or processed electroencephalography (EEG), or other specialized monitors are often used to estimate anesthetic depth to aid in avoiding awareness with recall, as discussed separately. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Monitoring'</a>.)</p><p>Other topics contain details regarding management of specific aspects of anesthesia during the maintenance phase:</p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of physiologic homeostasis including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oxygenation and ventilation (see  <a class="medical medical_review" href="/d/html/93386.html" rel="external">"Mechanical ventilation during anesthesia in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamic stability (see  <a class="medical medical_review" href="/d/html/94532.html" rel="external">"Hemodynamic management during anesthesia in adults"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Temperature control (see  <a class="medical medical_review" href="/d/html/94588.html" rel="external">"Perioperative temperature management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of awareness with recall (see  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antinociception (analgesia) during increased intensity of the degree of noxious surgical stimulation (see  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle relaxation to facilitate surgery and/or prevent movement as necessary for certain surgical procedures (see  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia"</a>)</p><p></p><p class="headingAnchor" id="H4262845011"><span class="h2">Anesthetic depth</span><span class="headingEndMark"> — </span>We individually titrate anesthetic agents to achieve an appropriate depth. We avoid excessive anesthetic depth and we avoid BP significantly lower than baseline values or frank hypotension, particularly in older patients and those at risk for development of perioperative neurocognitive disorders [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/d/html/118691.html" rel="external">"Perioperative neurocognitive disorders in adults: Risk factors and mitigation strategies", section on 'Avoid excessive depth during general anesthesia'</a>.)</p><p>An association has been noted between increasing anesthetic depth (gauged by processed EEG such as the bispectral index [BIS] monitor) and decreased postoperative survival in some observational studies; however, most studies did not report blood pressure (BP) data [<a href="#rid4">4</a>]. Yet low BP due to deep anesthesia has the strongest association with mortality in studies that did include BP data [<a href="#rid5">5,6</a>]. In a 2019 randomized study of more than 6600 patients &gt;60 years old who were undergoing major surgery with a volatile inhalation anesthetic technique (see <a class="local">'Inhalation anesthetic agents and techniques'</a> below), lighter anesthesia targeting BIS values at 50 (median 47; range 44 to 51) was compared with deeper anesthesia targeting BIS values at 35 (median 39; range 36 to 42), while appropriate BP was maintained in all patients [<a href="#rid7">7</a>]. In patients maintained with lighter anesthesia, mean arterial BP was slightly higher (3.5 mmHg), while volatile anesthetic use was 30 percent lower (with a minimum alveolar concentration [MAC] of 0.62; range 0.52 to 0.73 versus a MAC of 0.88; range 0.74 to 1.04). One-year mortality was the same in both groups [<a href="#rid7">7</a>]. </p><p>Also, neuromonitoring techniques such as processed EEG are often employed for patients at risk for awareness. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Brain monitoring'</a>.).</p><p class="headingAnchor" id="H1704129256"><span class="h1">SELECTION OF MAINTENANCE TECHNIQUES</span><span class="headingEndMark"> — </span>Maintenance of general anesthesia may be accomplished using a primary inhalation technique (see <a class="local">'Inhalation anesthetic agents and techniques'</a> below) or a primary intravenous (IV) technique (see <a class="local">'Total intravenous anesthesia'</a> below). A 2022 meta-analysis of randomized trials noted that choice of IV anesthesia with <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> versus inhalation anesthesia with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> did not affect mean inflammatory biomarker levels measured after various types of surgery (23 studies; 1611 participants) [<a href="#rid8">8</a>]. </p><p>Combinations that include one or more sedative-hypnotic agents (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> or an inhalation anesthetic) and one or more analgesics (eg, an opioid or nonopioid analgesic agent), with or without use of a neuromuscular blocking agent (NMBA) are often employed to achieve "balanced" general anesthesia [<a href="#rid9">9-12</a>]. </p><p>Ideal anesthetic maintenance agents have rapid onset of action, minimal cardiopulmonary or other side effects, and are cleared from the bloodstream quickly to ensure a rapid recovery. None of the available inhalation or IV anesthetic agents is ideal for all patients, and all have potential adverse side effects. Balanced (ie, multimodal) anesthetic techniques may increase the likelihood of achieving the desired goals (see <a class="local">'Anesthetic goals'</a> above), while using less of each drug than if it were administered alone by taking advantage of the synergism that occurs when anesthetic agents from different classes are combined [<a href="#rid9">9-13</a>]. However, the synergistic effects of such drug combinations may result in adverse effects such as hypotension or delayed emergence.</p><p class="headingAnchor" id="H1762635082"><span class="h1">INHALATION ANESTHETIC AGENTS AND TECHNIQUES</span><span class="headingEndMark"> — </span>All available volatile inhalation anesthetic agents (<a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, and in some countries halothane) may be used for complete maintenance of general anesthesia. An inhalation anesthetic technique may also include one gas (<a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> [N<sub>2</sub>O]) administered as a supplemental agent. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Maintenance of general anesthesia (all inhalation agents)'</a>.)</p><p class="headingAnchor" id="H302283397"><span class="h2">Dosing considerations</span><span class="headingEndMark"> — </span>Dosing of each inhalation anesthetic agent is determined by its potency, reported as the minimum alveolar concentration (MAC) value  (<a class="graphic graphic_table graphicRef109494" href="/d/graphic/109494.html" rel="external">table 2</a>), with 1 MAC being the concentration of an inhaled agent in the alveoli required to prevent movement in response to a surgical stimulus in 50 percent of patients  (<a class="graphic graphic_table graphicRef109424" href="/d/graphic/109424.html" rel="external">table 3</a>). MAC values are influenced by patient age and coexisting diseases or conditions  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'MAC and MAC-awake values for inhalation agents'</a>.)</p><p>Titration of the potent inhalation anesthetic is necessary to maintain stage III surgical anesthesia with unconsciousness, amnesia, immobility, and absence of response to noxious stimulation. Doses of the volatile agent are decreased if N<sub>2</sub>O is also inhaled and/or if intravenous (IV) anesthetic agent(s) are also administered [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Influence of drug-drug interactions'</a>.) </p><p class="headingAnchor" id="H1782839263"><span class="h2">Volatile inhalation agents</span></p><p class="headingAnchor" id="H392710961"><span class="h3">Advantages and disadvantages</span><span class="headingEndMark"> — </span>The potent volatile inhalation anesthetic agents share common advantages and disadvantages (see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Clinical effects'</a>): </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ease of administration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reliable blockade of responses to sensory input such as painful stimuli [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bronchodilation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent decreases in skeletal and smooth muscle tone.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased cerebral metabolic rate (CMR).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased cerebral blood flow (CBF).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ability to monitor end-tidal anesthetic concentration (ETAC) as an indicator of anesthetic depth; ETAC values of 0.8 to 1 MAC are typically adequate to prevent awareness with recall. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'End-tidal anesthetic concentration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent suppression of airway reflexes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent respiratory depression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose-dependent myocardial depression and vasodilation that may cause hypotension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased risk of postoperative nausea and vomiting (PONV) compared with most IV anesthetic alternatives, unless prophylactic antiemetics are administered. (See  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Anesthetic factors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential to induce malignant hyperthermia in susceptible individuals. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Other clinical effects'</a>.)</p><p></p><p class="headingAnchor" id="H1985653636"><span class="h3">Specific volatile inhalation agents</span><span class="headingEndMark"> — </span>The available potent volatile agents differ in their specific advantages and adverse effects, which affects selection for the maintenance phase of general anesthesia. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Specific inhalation anesthetic agents'</a>.)</p><p class="headingAnchor" id="H12592428"><span class="h4">Sevoflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> is often selected for maintenance of anesthesia during surgical procedures lasting less than two hours due to its low blood and tissue solubilities. Compared with older potent inhalation agents that have higher blood and tissue solubilities (eg, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>), uptake during induction, changes in anesthetic depth during the maintenance phase of general anesthesia, and emergence are more rapid when sevoflurane is used. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Advantages'</a>.)</p><p>A disadvantage for <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> use as the primary maintenance agent during longer surgical procedures is cost, particularly when higher fresh gas flows (ie, &gt;2 L/minute of oxygen and/or air) are employed to deliver it. Compared with <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, there is little advantage for faster recovery after delivery of sevoflurane for more than two hours because the blood:fat partition coefficients of these agents are similar. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p>Further details regarding <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Sevoflurane'</a>.)</p><p class="headingAnchor" id="H55659542"><span class="h4">Desflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a> has the lowest blood and tissue solubility of the potent volatile inhalation agents, resulting in very rapid uptake and elimination with little accumulation in tissues. Thus, changes in anesthetic depth and recovery during emergence are rapid [<a href="#rid16">16,17</a>]. Use of desflurane is particularly advantageous in patients who are older, morbidly obese, or have sleep apnea [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Advantages'</a>.)</p><p>Similar to <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, a disadvantage of <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> is its high cost during use as the primary maintenance agent for longer surgical procedures. Other disadvantages include pungency with a very high incidence of airway irritation (eg, coughing, salivation, breath-holding, laryngospasm), and sympathomimetic properties that result in tachycardia and hypertension, particularly if higher or abruptly increased concentrations are administered. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p>Further details regarding <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Desflurane'</a>.)</p><p class="headingAnchor" id="H55659579"><span class="h4">Isoflurane</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a> is commonly used as a primary agent to maintain general anesthesia during longer surgical cases. It is the more potent than <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> or <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, inexpensive, and widely available. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Advantages'</a>.)</p><p>Disadvantages of <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> compared with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a> or <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a> include slower onset during induction and slower recovery due to higher blood and tissue solubility. Thus, emergence may be prolonged, particularly after a long duration of administration. Other disadvantages include pungency with potential airway irritation during induction and emergence. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p>Further details regarding <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a> administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Isoflurane'</a>.)</p><p class="headingAnchor" id="H55659602"><span class="h4">Halothane</span><span class="headingEndMark"> — </span>Concern about hepatotoxicity has eliminated the use of halothane in North America; however it is still commonly used in some regions, particularly in pediatric patients. </p><p>Halothane has the slowest onset and recovery of any of the potent inhalation agents due to very high tissue and blood solubility. Emergence from anesthesia may be prolonged compared with other potent volatile agents. Other disadvantages include potential hepatotoxicity, as well as negative inotropy and chronotropy, and a high incidence of ventricular and other dysrhythmias. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.) </p><p>Advantages include its very high potency and low cost. In addition, halothane is a bronchodilating agent with little airway irritability. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Advantages'</a>.) </p><p>Further details regarding halothane administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Halothane'</a>.)</p><p class="headingAnchor" id="H283253190"><span class="h2">Nitrous oxide gas</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> (N<sub>2</sub>O) is a pressurized gas that is delivered via a flow meter on the anesthesia machine. N<sub>2</sub>O gas is often selected as a supplemental agent during maintenance of general anesthesia with either an inhalation or IV anesthetic technique. Its use increases anesthetic depth, resulting in decreased dose requirements for coadministered anesthetic agents. In a review of the available evidence, the European Society of Anaesthesiologists Task Force on Nitrous Oxide concluded that a rational approach is targeted use of N<sub>2</sub>O considering its risk/benefit ratio in any given patient, as with other anesthetic agents [<a href="#rid19">19</a>]. The authors routinely use N<sub>2</sub>O in the absence of contraindications. However, N<sub>2</sub>O cannot be used as a sole agent to maintain anesthesia because of its low potency (the MAC value is 104 percent). (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Typical uses'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages </strong>– Advantages of N<sub>2</sub>O include [<a href="#rid19">19,20</a>] (see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Advantages'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid onset and offset due to its very low blood solubility. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Partition coefficients and potency'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During the maintenance phase of general anesthesia, coadministration of N<sub>2</sub>O with any potent volatile inhalation agent allows more rapid changes in anesthetic depth due to a phenomenon termed the "second gas" effect. Similarly, speed of induction and emergence are increased with coadministration of N<sub>2</sub>O due to dilution of the alveolar concentration of the volatile anesthetic. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Analgesic properties.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anxiolytic properties.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minimal hemodynamic effects.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cheap and wide availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages </strong>– Disadvantages include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential for diffusion into any air-filled cavity, displacing nitrogen gas. Thus, administration is avoided in patients with possible pre-existing bowel distention, increased middle ear pressure, pneumothorax, pneumoperitoneum, pneumocephalus, intraocular gas, or venous air embolism. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although visceral distension may slightly increase risk of PONV, particularly if no antiemetic prophylactic measures are employed, this does not preclude its use in patients without contraindications [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Anesthetic factors'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential for transient diffusion hypoxia if N<sub>2</sub>O is discontinued at a low inspired oxygen concentration. In this circumstance, bulk transfer of N<sub>2</sub>O gas into the alveolus displaces oxygen, thereby decreasing alveolar oxygen concentration and potentially inducing desaturation. Diffusion hypoxia may be prevented by delivery of high inspired oxygen concentration for several minutes before and after discontinuing N<sub>2</sub>O. (See  <a class="medical medical_review" href="/d/html/94534.html" rel="external">"Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'</a>.)</p><p></p><p>Reevaluation of available evidence suggests that the perceived drawbacks of N<sub>2</sub>O (eg, nausea, vomiting, bowel distension) have been exaggerated or misdirected. We do not specifically avoid N<sub>2</sub>O unless there is a contraindication for its use [<a href="#rid19">19</a>]. Further details regarding N<sub>2</sub>O administration are discussed separately. (See  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Nitrous oxide'</a>.)</p><p class="headingAnchor" id="H179249047"><span class="h1">INTRAVENOUS ANESTHETIC AGENTS AND TECHNIQUES</span></p><p class="headingAnchor" id="H2377657342"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Appropriate doses of intravenous (IV) anesthetic agents are titrated to maintain stage III surgical anesthesia with unconsciousness, amnesia, immobility, and absence of response to noxious stimulation, similar to considerations for inhalation anesthetic agents. (See <a class="local">'Anesthetic goals'</a> above and <a class="local">'Dosing considerations'</a> above.)</p><p>When IV anesthetic drugs from different classes are combined, the hypnotic effects are often synergistic rather than merely additive, requiring dose reductions for each agent. Synergy is particularly common when drugs acting primarily on gamma-aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptors (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) are combined with drugs acting on other receptor types (eg, opioids, alpha<sub>2</sub> agonists such as <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>) [<a href="#rid9">9</a>]. Similarly, doses of IV agents should be reduced when an inhalation agent such as <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> (N<sub>2</sub>O) or a potent volatile anesthetic agent is coadministered. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Dosing considerations'</a> and  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Influence of drug-drug interactions'</a>.)</p><p class="headingAnchor" id="H7869294"><span class="h2">Total intravenous anesthesia</span><span class="headingEndMark"> — </span>Total intravenous anesthesia (TIVA) employs a sedative-hypnotic anesthetic (typically <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) and an analgesic component (typically an opioid agent). Adjuncts such as <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, or <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> infusions may be used for patient-specific or procedure-specific reasons to replace or minimize the total propofol and/or total opioid doses [<a href="#rid21">21</a>]. Overall, these adjunct agents have limited benefits and specific potential adverse effects, as noted below.</p><p>Guidelines for the safe practice of TIVA were jointly published in 2019 by the Association of Anaesthetists, the Society for Intravenous Anesthesia in Great Britain [<a href="#rid22">22</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion doses of the IV agents are adjusted based on age, frailty, and comorbid medical conditions. Typically, a low initial infusion setting (eg, of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) is adjusted by making small incremental increases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug and fluid lines should be as close to the patient as possible to minimize dead space. Whenever possible, the IV catheter of central venous catheter through which the infusion is being delivered should be visible throughout the anesthetic care. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidelines for use of IV infusion pumps, including smart pumps, syringe pumps, and target-controlled infusion (TCI) devices are discussed separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Smart pumps'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Syringe pumps'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Target-controlled infusion systems'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns include the possibility of awareness during anesthesia (see  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Brain monitoring'</a>), or, conversely, excessive anesthetic depth with delayed recovery (see  <a class="medical medical_review" href="/d/html/118691.html" rel="external">"Perioperative neurocognitive disorders in adults: Risk factors and mitigation strategies", section on 'Avoid excessive depth during general anesthesia'</a>). For this reason, raw or processed electroencephalography (EEG) monitoring (eg, the bispectral index [BIS]) or other neuromonitoring techniques are often used to aid intraoperative dosing  (<a class="graphic graphic_table graphicRef81084" href="/d/graphic/81084.html" rel="external">table 5</a>) [<a href="#rid22">22-24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and advantages </strong>– A TIVA technique is selected in the following circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients requiring general anesthesia if there are absolute contraindications (eg, history of malignant hyperthermia) (see  <a class="medical medical_review" href="/d/html/401.html" rel="external">"Malignant hyperthermia: Diagnosis and management of acute crisis", section on 'MH triggers'</a>) or relative contraindications (eg, high risk for postoperative nausea and vomiting [PONV]) (see  <a class="medical medical_review" href="/d/html/16849.html" rel="external">"Postoperative nausea and vomiting", section on 'Anesthetic factors'</a>) for administration of volatile agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients undergoing surgical procedures with neuromonitoring (eg, spine surgery) because use of a sedative hypnotic (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) and an opioid agent has less effect on evoked potentials than potent volatile inhalation agents or N<sub>2</sub>O. In particular, motor evoked potentials (MEPs) are very sensitive to inhalation agents, while somatosensory-evoked potentials (SSEPs) are moderately affected. However, propofol causes a dose-dependent decrease in EEG amplitude and frequency, ultimately producing burst suppression and electrical silence at high doses. (See  <a class="medical medical_review" href="/d/html/91216.html" rel="external">"Neuromonitoring in surgery and anesthesia", section on 'Anesthetic effects on neuromonitoring'</a> and  <a class="medical medical_review" href="/d/html/91216.html" rel="external">"Neuromonitoring in surgery and anesthesia", section on 'Maintenance of anesthesia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages </strong>– Potential disadvantages of TIVA include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood concentrations (and therefore effect site concentration) of IV anesthetic agents are not easily obtained. This contrasts with inhalation anesthetics, for which the exhaled end-tidal anesthetic concentration (ETAC) of each agent can be continuously monitored, allowing real-time dose adjustments of anesthetic depth. Although processed or unprocessed EEG indices or other neuromonitoring techniques are often used to titrate anesthetic agents during TIVA, such indices do not reliably confirm that patients are not aware. However, a 2017 meta-analysis concluded that use of processed EEG (eg, BIS) monitoring to guide TCI of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> dosing allows better maintenance of the target anesthetic depth compared with manual control based on standard monitoring [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Total intravenous anesthesia'</a> and  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Brain monitoring'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TIVA is associated with dose-dependent suppression of airway reflexes and respiratory depression, similar to potent volatile inhalation agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TIVA is also associated with dose-dependent vasodilation and myocardial depression that may cause hypotension, similar to potent volatile inhalation agents.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the limb containing the IV catheter is tucked at the patient's side table or not continuously visible due to surgical draping, unrecognized IV infiltration and extravasation of a continuous IV infusion into the tissue of a tucked limb can occur, resulting in compartment syndrome. Also, unrecognized disconnection of the IV tubing from the catheter may result in failure to administer the intended medication. (See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Extravasation of a continuous infusion'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible errors in IV drug delivery via infusion devices include syringe pump or "smart" pump setting errors that may go undetected (eg, wrong rate, wrong dose, wrong concentration, wrong medication), failure to deliver the intended agent, overriding soft limits with consequent overdosing, or underdosing with possible awareness. (See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Risks for medication errors'</a> and  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Smart pumps'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TIVA anesthetic techniques are typically more costly than inhalation techniques, depending on which specific IV agents are selected [<a href="#rid25">25,26</a>]. Target-controlled infusion (TCI) systems are not currently approved in the United States for clinical use during TIVA techniques. (See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Target-controlled infusion systems'</a>.)</p><p></p><p class="headingAnchor" id="H536321029"><span class="h2">Specific intravenous agents</span></p><p class="headingAnchor" id="H4116923945"><span class="h3">Sedative-hypnotic agent: Propofol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is usually selected as the sedative-hypnotic component to maintain general anesthesia during a TIVA technique.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing </strong>– <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is typically administered as a continuous infusion using a syringe pump or a smart pump that requires operator programming. Although not available in the United States, closed-loop TCI systems are used in some countries for delivery of propofol during a TIVA technique. However, intersubject variability (eg, obesity, underweight status) in pharmacokinetic and pharmacodynamic parameters used in models to calculate the drug concentration of propofol at the effect site has limited utility of TCI systems. (See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use"</a> and  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Target-controlled infusion systems'</a>.)</p><p></p><p class="bulletIndent1">The typical dose range for <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> is 75 to 150 mcg/kg per minute in younger and healthier patients who can tolerate these higher doses. Propofol dosing is reduced by factors such as older age, hypovolemia, vasodilation, myocardial dysfunction, and coadministration of other agents, as discussed separately. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Dosing considerations'</a>.)</p><p></p><p class="bulletIndent1">Ideally, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> dosing is titrated using EEG-based neuromonitoring, although other technology has been used in some centers (eg, isolated forearm technique) (see  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Brain monitoring'</a>). The infusion rate is titrated to the patient's responses to noxious surgical stimulation when such monitoring technology is not available. In some countries, TCI systems are used to predict the propofol concentration in the plasma and at the effect site (ie, the brain); however, TCI systems are not available in the United States [<a href="#rid23">23,27</a>]. (See  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Target-controlled infusion systems'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages and potential adverse effects </strong>– Advantages of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> include rapid onset and recovery  (<a class="graphic graphic_figure graphicRef118712" href="/d/graphic/118712.html" rel="external">figure 1</a>), and antiemetic, anticonvulsant, antipruritic, and bronchodilatory properties. It is suitable for patients with renal and/or hepatic insufficiency (see  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Advantages and beneficial effects'</a>). When used as the sedative-hypnotic component of a TIVA technique during maintenance of general anesthesia, propofol may also have beneficial antioxidant, antiinflammatory, and immunomodulatory effects [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">Clinically significant adverse side effects of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> are minimal, particularly when titrated to desired depth. However, hypotension can occur at higher doses in susceptible patients, primarily due to venous and arterial dilation. Dose-dependent respiratory depression is also a known side effect. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="headingAnchor" id="H3091180746"><span class="h3">Benzodiazepine: remimazolam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">Remimazolam</a> is a novel benzodiazepine developed in Japan for use as an induction and maintenance anesthetic agent. Remimazolam is ultra-short acting and it is metabolized by non-specific tissue esterases [<a href="#rid29">29</a>]. In bolus dose it is cleared three times as quickly as <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> [<a href="#rid30">30</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – As a component of TIVA general anesthesia, maintenance doses of <a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">remimazolam</a> are approximately 1 mg/kg per hour [<a href="#rid31">31</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages and potential adverse effects</strong> – <a class="drug drug_general" data-topicid="128915" href="/d/drug information/128915.html" rel="external">Remimazolam</a> has faster clearance than <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> [<a href="#rid30">30</a>]. Although data are scant, its safety profile and side effects (eg, respiratory depression, hypotension, bradycardia) are similar to <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> [<a href="#rid31">31,32</a>]. However, some case reports of anaphylaxis have been published [<a href="#rid33">33-35</a>]. Although remimazolam is licensed in the United States, clinical use will likely be limited pending further studies.</p><p></p><p class="headingAnchor" id="H861399748"><span class="h3">Analgesic component: Opioid agents</span><span class="headingEndMark"> — </span>An opioid is usually selected to provide the analgesic component of a TIVA technique.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – In general, we use the lowest dose of opioid for the shortest period of time necessary, while ensuring provision of adequate analgesia [<a href="#rid36">36-38</a>]. </p><p></p><p class="bulletIndent1">Protocols for enhanced recovery after surgery (ERAS) emphasize limiting the dose of perioperative opioids because of potential adverse effects in the postoperative period (see below). Multimodal opioid-sparing strategies in such protocols include administration of nonopioid analgesics such as <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2 specific inhibitors, and adjuvant agents with analgesic properties (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>), as well as use of nonpharmacologic analgesic techniques such as regional blocks. Further discussion is found in other topics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/113724.html" rel="external">"Anesthetic management for enhanced recovery after major noncardiac surgery (ERAS)", section on 'Pain prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/113724.html" rel="external">"Anesthetic management for enhanced recovery after major noncardiac surgery (ERAS)", section on 'Management of pain'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/130312.html" rel="external">"Approach to the management of acute pain in adults", section on 'Creating a plan for analgesia'</a>.)</p><p></p><p class="bulletIndent1">Some clinicians advocate "opioid-free" anesthesia, whereby multimodal nonopioid analgesic agents and techniques are used rather than administering any intraoperative (or postoperative) opioid. However, data are insufficient to recommend patient-specific or procedure-specific indications for such complete opioid avoidance [<a href="#rid13">13,39-42</a>]. In an individual patient, it remains essential to ensure effective intraoperative and postoperative analgesia if opioids are minimized or avoided [<a href="#rid36">36,37,43</a>]. (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Opioid-free and opioid-sparing anesthetic techniques'</a> and <a class="local">'Adjuvant agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages and potential adverse effects </strong>– Benefits of opioids include effective analgesia, reduced requirements for other IV and inhalation anesthetic agents, attenuation of autonomic responses to noxious stimuli, and blunting of cough and gag reflexes during airway manipulation. (See  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Benefits'</a>.)</p><p></p><p class="bulletIndent1">Potential adverse effects of opioids during and after general anesthesia include (see  <a class="medical medical_review" href="/d/html/94536.html" rel="external">"Perioperative uses of intravenous opioids in adults: General considerations", section on 'Prevention and management of adverse opioid effects'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative period – Exacerbation of adverse effects of other anesthetic agents (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, inhalation anesthetics) including hypotension and respiratory depression may occur. Other potential adverse effects include bradycardia, chest wall and skeletal muscle rigidity, and delayed emergence.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative period – Nausea and vomiting, delirium, pruritus, urinary retention, and potential for acute tolerance and opioid-induced hyperalgesia may occur in the postoperative period.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of an opioid agent </strong>– Selection of a specific opioid and dosing considerations depend on procedure-specific factors (eg, degree of analgesia required, planned duration of surgery), patient-specific factors (eg, age, comorbidities, tolerance to opioids), the desired speed of onset and offset, and whether other analgesic agents are coadministered. (See  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous infusion during a TIVA anesthetic technique – <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a> is often selected for continuous infusion during a TIVA technique, particularly during shorter procedures when the intensity of noxious surgical stimulation is expected to vary considerably. When coadministered with <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, dose-dependent analgesic effects of remifentanil reduce somatic movement and autonomic nervous system  (<a class="graphic graphic_figure graphicRef126668" href="/d/graphic/126668.html" rel="external">figure 2</a>), and these effects are more marked for painful stimuli than for nonpainful stimuli such as calling the patient's name [<a href="#rid15">15</a>]. However, when coadministered with <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, these effects diminish with higher remifentanil concentrations (eg, &gt;2 ng/mL predicted effect site concentration, which is approximately equivalent to a continuous infusion of remifentanil at 0.1 ng/kg per minute)  (<a class="graphic graphic_figure graphicRef126668" href="/d/graphic/126668.html" rel="external">figure 2</a>) [<a href="#rid15">15</a>].  </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9954" href="/d/drug information/9954.html" rel="external">Sufentanil</a> may be selected as an alternative opioid infusion for longer TIVA anesthetics due to its lower cost. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bolus dosing – A short-acting opioid such as <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a> is typically selected for bolus dosing during a TIVA anesthetic technique or to provide supplemental analgesia during general anesthesia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative dosing to provide postoperative analgesia – A long-acting opioid (eg, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> or <a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">hydromorphone</a>) is typically selected, and administered approximately 20 to 30 minutes before emergence from general anesthesia if significant postoperative pain is anticipated. </p><p></p><p class="bulletIndent1">Agent-specific uses, dosing, advantages, disadvantages, drug-drug interactions, and pharmacokinetics for opioids employed during general anesthesia are described separately  (<a class="graphic graphic_table graphicRef111779" href="/d/graphic/111779.html" rel="external">table 6</a> and <a class="graphic graphic_figure graphicRef109503" href="/d/graphic/109503.html" rel="external">figure 3</a> and <a class="graphic graphic_figure graphicRef109502" href="/d/graphic/109502.html" rel="external">figure 4</a> and <a class="graphic graphic_figure graphicRef109504" href="/d/graphic/109504.html" rel="external">figure 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">Remifentanil</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Remifentanil'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">Fentanyl</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Fentanyl'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9954" href="/d/drug information/9954.html" rel="external">Sufentanil</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Sufentanil'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9347" href="/d/drug information/9347.html" rel="external">Alfentanil</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Alfentanil'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8538" href="/d/drug information/8538.html" rel="external">Hydromorphone</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Hydromorphone'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> (see  <a class="medical medical_review" href="/d/html/130113.html" rel="external">"Perioperative uses of intravenous opioids: Specific agents", section on 'Morphine'</a>)</p><p></p><p class="headingAnchor" id="H128608533"><span class="h3">Adjuvant agents</span><span class="headingEndMark"> — </span>Infusions of other adjuvant agents (eg, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>  (<a class="graphic graphic_figure graphicRef118712" href="/d/graphic/118712.html" rel="external">figure 1</a>)) may be used to reduce or replace <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> as the sedative-hypnotic component or an opioid as the analgesic component of a TIVA technique. Addition of such adjuvant agents results in synergistic rather than merely additive effects [<a href="#rid9">9-11</a>]. However, data are scant regarding specific combinations of anesthetic agents; thus, limited knowledge exists regarding potential clinical benefits and adverse effects of such combinations. Dose reduction of all administered agents is appropriate when these synergistic effects result in undesirable decreases in blood pressure.</p><p class="headingAnchor" id="H128608633"><span class="h4">Dexmedetomidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">Dexmedetomidine</a> is a highly selective alpha<sub>2</sub> agonist acting on receptors in the brain and spinal cord. Dexmedetomidine is not routinely used as an adjunct to reduce dosing of sedative-hypnotic and opioid agents during maintenance of general anesthesia. Its use as a sedative in intraoperative interventions and intensive care unit are discussed in separate topics. (See  <a class="medical medical_review" href="/d/html/94529.html" rel="external">"Monitored anesthesia care in adults", section on 'Dexmedetomidine'</a> and  <a class="medical medical_review" href="/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient", section on 'Dexmedetomidine'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Data are limited regarding optimal dosing during coadministration of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> with hypnotic intravenous or potent inhalation anesthetic agents. It is typically administered as a continuous infusion at 0.1 to 0.3 mcg/kg per hour, although higher doses up to 0.8 mcg/kg per hour are sometimes used. Dosing should be reduced in patients with hepatic insufficiency since dexmedetomidine is heavily protein-bound; thus, its elimination half-life may be prolonged [<a href="#rid44">44</a>]. Also, dosing is reduced in patients with reduced hepatic blood flow such as those with low cardiac output, and in older adults due to age-related decline in hepatic mass and function [<a href="#rid45">45,46</a>] (see  <a class="medical medical_review" href="/d/html/14931.html" rel="external">"Anesthesia for the older adult", section on 'Intravenous anesthetic and adjuvant agents'</a>). Clearance of dexmedetomidine is not affected by fat mass in obese patients; thus, weight-based dosing may result in higher than necessary plasma concentrations [<a href="#rid47">47</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages </strong>– Advantages of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> include its analgesic, sedative, anxiolytic, antiemetic, and sympatholytic properties [<a href="#rid48">48</a>]. In particular, the analgesic effects of dexmedetomidine result in opioid-sparing effects [<a href="#rid49">49,50</a>]. In a randomized trial in 90 patients, a single intraoperative bolus dose of dexmedetomidine 0.5 mcg/kg reduced remifentanil-induced hyperalgesia [<a href="#rid51">51</a>]. Also, dexmedetomidine reduces requirements for <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> or potent inhalation anesthetics in a synergistic fashion; however, the degree of synergism remains unknown [<a href="#rid9">9,52</a>]. However, data regarding the overall efficacy and clinical significance of dexmedetomidine-induced decreases in postoperative pain and opioid requirements are inconsistent [<a href="#rid53">53-55</a>]. </p><p></p><p class="bulletIndent1">In a 2020 meta-analysis, administration of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> during the perioperative period was associated with less postoperative nausea and vomiting (PONV) [<a href="#rid56">56</a>]. However, this study has significant limitations because the use of routine PONV prophylaxis was not considered, thus questioning the clinical utility of the conclusions.</p><p></p><p class="bulletIndent1">Some studies suggest that intraoperative administration of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> ameliorates or reduces the incidence of agitated emergence delirium [<a href="#rid57">57-59</a>] or postoperative delirium [<a href="#rid60">60</a>]. However, data are not consistent [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/118691.html" rel="external">"Perioperative neurocognitive disorders in adults: Risk factors and mitigation strategies", section on 'Intravenous agents associated with lower risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages and adverse effects </strong>– Adverse effects of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> include the potential to cause hypotension and/or bradycardia due to its sympatholytic effects, particularly if coadministered with other agents that also cause these effects (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> or inhalation agents) [<a href="#rid52">52,63</a>]. In one randomized trial in 80 patients undergoing laparoscopic surgery, addition of a continuous infusion of dexmedetomidine to a continuous infusion of propofol administered via a closed-loop anesthesia delivery system (see  <a class="medical medical_review" href="/d/html/110370.html" rel="external">"Intravenous infusion devices for perioperative use", section on 'Target-controlled infusion systems'</a>) resulted in consistent reduction of propofol requirements [<a href="#rid52">52</a>]. However, in this study, addition of dexmedetomidine increased the incidence of significant bradycardia (9 versus 41 percent) and hypotension (6 versus 26 percent), and increased time to emergence and degree of sedation in the early postoperative period. In another randomized trial in 312 patients, those receiving balanced opioid-free anesthesia with a dexmedetomidine infusion at 0.4 to 1.4 mcg/kg per hour had a higher incidence of hypoxemia and severe bradycardia, as well as delayed extubation and prolonged stay in the postanesthesia care unit (PACU), compared with those receiving an infusion of the short-acting opioid <a class="drug drug_general" data-topicid="9854" href="/d/drug information/9854.html" rel="external">remifentanil</a> at 0.1 to 0.25 mcg/kg per minute [<a href="#rid61">61</a>]. Other studies have demonstrated similar adverse effects of dexmedetomidine infusion used as an adjunct agent for maintenance of anesthesia [<a href="#rid24">24,63-66</a>].</p><p></p><p class="bulletIndent1">Assessment of dexmedetomidine-induced level of sedation is difficult [<a href="#rid67">67</a>]. Also, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a> has a variable context-sensitive half-time that depends on the duration of a continuous infusion (eg, four minutes after infusion for 10 minutes; 250 minutes after infusion for eight hours). This leads to difficulty in decisions regarding optimal timing for discontinuation of dexmedetomidine in order to prepare for emergence from general anesthesia. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Discontinue anesthetic agents'</a>.)</p><p></p><p class="bulletIndent1">Furthermore, resolution occurs gradually after discontinuation of <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>. Thus, relative overdosing, respiratory depression, hemodynamic depression of heart rate and blood pressure, residual sedation, and delayed recovery may persist in the early postoperative period, particularly after coadministration of dexmedetomidine with a sedative-hypnotic or opioid [<a href="#rid52">52,64</a>]. (See  <a class="medical medical_review" href="/d/html/94529.html" rel="external">"Monitored anesthesia care in adults", section on 'Dexmedetomidine'</a>.)</p><p></p><p class="headingAnchor" id="H128608667"><span class="h4">Ketamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> is an N-methyl-d-aspartate receptor antagonist that produces dissociative anesthesia (profound analgesia while appearing disconnected from surroundings) [<a href="#rid68">68</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Dosing during a TIVA technique begins with an IV bolus of 0.25 to 0.35 mg/kg, followed by infusion of less than 1 mg/kg per hour. There is no role for a single dose of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> during the maintenance phase of anesthesia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages </strong>– <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> has anesthetic and excellent analgesic effects that reduce requirements for other anesthetic agents (eg, <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, potent inhalation anesthetics). It is often used in opioid-tolerant patients undergoing major surgical procedures, particularly when regional analgesic techniques are not possible [<a href="#rid69">69</a>]. Ketamine maintains airway reflexes and respiratory drive, which is advantageous in patients who are breathing spontaneously, and also has excellent bronchodilatory properties. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Advantages and beneficial effects'</a>.)</p><p></p><p class="bulletIndent1">In cases when neuromonitoring is necessary, a <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> infusion may be used as an adjuvant agent because it beneficially augments motor evoked potential (MEP) and somatosensory evoked potential (SSEP) amplitudes [<a href="#rid70">70,71</a>]. (See  <a class="medical medical_review" href="/d/html/91216.html" rel="external">"Neuromonitoring in surgery and anesthesia", section on 'Intravenous agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages and adverse effects </strong>– <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">Ketamine</a> increases sympathetic tone with typical increases in blood pressure, heart rate, and cardiac output, which may be beneficial in patients with hemodynamic instability, but may be detrimental in patients with ischemic heart disease or systemic hypertension. Furthermore, these sympathomimetic effects increase pulmonary artery pressure and intracranial pressure, effects which may be detrimental in patients with pulmonary hypertension or elevated intracranial pressure (ICP). (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'</a>.)</p><p></p><p class="bulletIndent1">Other potential adverse effects of <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> include psychotomimetic effects that may cause hallucinations, nightmares, and vivid dreams during and shortly after emergence from anesthesia. Even single low doses of ketamine used for induction of anesthesia (0.5 mg to 1 mg/kg) can induce such negative experiences [<a href="#rid72">72</a>]. Thus, ketamine is typically reserved for opioid-tolerant patients who are undergoing painful surgery in order to avoid or limit opioid dosing [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/93871.html" rel="external">"Delayed emergence and emergence delirium in adults", section on 'Evaluation and treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1040315391"><span class="h4">Lidocaine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">Lidocaine</a> is a local anesthetic agent that is often used during IV induction of general anesthesia to suppress airway reflexes, reduce the pain of injection of other induction agents, and supplement their anesthetic effects. Lidocaine infusion is occasionally used during maintenance of general anesthesia as a component of a multimodal analgesia technique. (See  <a class="medical medical_review" href="/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Lidocaine'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – When used during the maintenance phase, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> is administered as a 1 to 1.5 mg/kg bolus, followed by continuous infusion of 1 to 1.5 mg/kg per hour (or 2 mg/minute in some studies) [<a href="#rid73">73-75</a>]. Notably, calculated doses should be based on lean or adjusted body weight, rather than on actual body weight (<a class="calc calc_professional" href="/d/html/13408.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/d/html/13407.html" rel="external">calculator 2</a>) [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages </strong>– Some studies have reported that infusion of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> reduces opioid and sedative-hypnotic requirements and improves postoperative pain control after open or laparoscopic abdominal surgery, particularly if regional anesthetic techniques cannot be employed, and lidocaine may also improve pain control and reduce airway reactivity in patients undergoing head and neck procedures [<a href="#rid73">73-76</a>].</p><p></p><p class="bulletIndent1">However, the overall role of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> infusion as an analgesic adjunct is questionable. A 2018 meta-analysis concluded that lidocaine infusion does not have any beneficial effects on postoperative pain scores, opioid consumption, opioid-related adverse effects, or gastrointestinal recovery compared with placebo or no treatment [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages and adverse effects </strong>– Few studies have assessed adverse effects of administering a continuous IV infusion of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid77">77</a>]. However, the risk of local anesthesia systemic toxicity (LAST) may rarely occur due to inadvertent boluses of IV lidocaine or accidental infusion pump programming errors, and is potentially life-threatening [<a href="#rid78">78</a>]. Also, lidocaine has the potential to cause hypotension [<a href="#rid79">79,80</a>].</p><p></p><p class="headingAnchor" id="H3887431196"><span class="h1">NEUROMUSCULAR BLOCKING AGENTS</span></p><p class="headingAnchor" id="H3537362745"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>A neuromuscular blocking agent (NMBA) may be employed to improve surgical conditions in selected cases. </p><p>Two classes of NMBAs exist: depolarizing (<a class="drug drug_general" data-topicid="9952" href="/d/drug information/9952.html" rel="external">succinylcholine</a> [SCh]) and nondepolarizing agents (eg, <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a>, <a class="drug drug_general" data-topicid="10041" href="/d/drug information/10041.html" rel="external">vecuronium</a>, <a class="drug drug_general" data-topicid="9738" href="/d/drug information/9738.html" rel="external">pancuronium</a>, <a class="drug drug_general" data-topicid="8973" href="/d/drug information/8973.html" rel="external">atracurium</a>, <a class="drug drug_general" data-topicid="9270" href="/d/drug information/9270.html" rel="external">cisatracurium</a>, mivacurium)  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 7</a>). All nondepolarizing NMBAs have a slower onset and longer duration than SCh. A nondepolarizing NMBA is typically selected during the maintenance phase unless the surgical procedure is expected to last only a few minutes. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Classification of neuromuscular blocking agents'</a>.)</p><p>Intraoperative monitoring of the intensity of neuromuscular blockade is necessary throughout the maintenance phase of general anesthesia when a NMBA is administered [<a href="#rid81">81-83</a>]. (See  <a class="medical medical_review" href="/d/html/114324.html" rel="external">"Monitoring neuromuscular blockade"</a>.) </p><p class="headingAnchor" id="H3230944919"><span class="h2">Advantages and disadvantages</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advantages:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Muscle relaxation in the surgical field and/or complete absence of movement facilitates safety and technical performance in many surgical procedures, and may allow lower insufflation pressures during laparoscopy. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Facilitation of surgery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of an NMBA may reduce total administered doses of anesthetic agents. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Neuromuscular blockade'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disadvantages:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Risk of awareness is potentially increased since use of an NMBA may reduce the total administered doses of anesthetic agents, particularly when complete paralysis eliminates all purposeful movement. (See  <a class="medical medical_review" href="/d/html/400.html" rel="external">"Accidental awareness during general anesthesia", section on 'Neuromuscular blockade'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Residual neuromuscular block after administration of NMBAs is an important risk factor for anesthesia-related morbidity and mortality. Strategies to avoid residual block are discussed in detail in a separate topic. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia", section on 'Avoidance of residual neuromuscular blockade'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NMBAs, particularly <a class="drug drug_general" data-topicid="9872" href="/d/drug information/9872.html" rel="external">rocuronium</a> and SCh, have a relatively high incidence of anaphylaxis compared with other agents employed during general anesthesia. Anaphylaxis is more common in some countries (eg, Australia, New Zealand, France, and Norway), possibly due to immunologic cross-reactivity with pholcodine (an over-the-counter cough suppressant available in those countries). (See  <a class="medical medical_review" href="/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Neuromuscular-blocking agents'</a>.)</p><p></p><p class="headingAnchor" id="H2224858488"><span class="h2">Specific neuromuscular blocking agents</span><span class="headingEndMark"> — </span>Selection of a specific NMBA is based on the planned duration of the surgical procedure, presence of severe renal or hepatic dysfunction, the NMBA that was administered during anesthetic induction, whether the surgical procedure requires peripheral nerve stimulation or motor-evoked potential (MEP) monitoring, and availability and cost of each agent within an individual institution or country  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 7</a>). </p><p>Further details regarding use of NMBAs are discussed separately. (See  <a class="medical medical_review" href="/d/html/94535.html" rel="external">"Clinical use of neuromuscular blocking agents in anesthesia"</a>.)</p><p class="headingAnchor" id="H283253221"><span class="h1">TRANSITION TO THE EMERGENCE PHASE</span><span class="headingEndMark"> — </span>Emergence is the return of consciousness after discontinuing administration of anesthetic and adjuvant agents at the end of the surgical procedure. Most patients transition smoothly from a surgical anesthetic state (Stage III) to an awake state (Stage I)  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 1</a>). Preparations for emergence are discussed in a separate topic. (See  <a class="medical medical_review" href="/d/html/94537.html" rel="external">"Emergence from general anesthesia", section on 'Preparations for emergence'</a>.)</p><p class="headingAnchor" id="H3834081596"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals</strong> – Overall goals during the maintenance phase of a general anesthetic include maintaining Stage III surgical anesthesia (ie, unconsciousness, amnesia, immobility, and unresponsiveness to surgical stimulation  (<a class="graphic graphic_table graphicRef107796" href="/d/graphic/107796.html" rel="external">table 1</a>)) at a safe anesthetic depth, while also maintaining respiratory and hemodynamic stability. (See <a class="local">'Anesthetic goals'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – Maintenance of general anesthesia may be accomplished by employing a primary inhalation technique, a primary intravenous (IV) technique, or a combination of inhalation and IV agents. Coadministration of agents from different classes takes advantage of their synergistic effects, increasing the likelihood of achieving the desired anesthetic goals while using less of each drug than if it were administered alone. (See <a class="local">'Selection of maintenance techniques'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhalation anesthetic agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potent volatile inhalation agents</strong> – Specific advantages, disadvantages, and adverse effects differ among these agents, as described separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">Sevoflurane</a> (see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Sevoflurane'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">Desflurane</a><strong> </strong>(see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Desflurane'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">Isoflurane</a><strong> </strong>(see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Isoflurane'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Halothane (see  <a class="medical medical_review" href="/d/html/114826.html" rel="external">"Inhalation anesthetic agents: Clinical effects and uses", section on 'Halothane'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Dosing considerations</strong> – Dose titration of potent volatile inhalation agents is necessary to maintain stage III surgical anesthesia. Each inhalation anesthetic agent's potency is reported as a minimum alveolar concentration (MAC) value  (<a class="graphic graphic_table graphicRef109424" href="/d/graphic/109424.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef109494" href="/d/graphic/109494.html" rel="external">table 2</a>), which is influenced by patient age and coexisting diseases or conditions  (<a class="graphic graphic_table graphicRef109495" href="/d/graphic/109495.html" rel="external">table 4</a>). Dosing is decreased with concomitant administration of <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> (N<sub>2</sub>O) and/or if IV anesthetic agents. (See <a class="local">'Volatile inhalation agents'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Advantages</strong> – General advantages of the potent volatile inhalation agents (eg, <a class="drug drug_general" data-topicid="9887" href="/d/drug information/9887.html" rel="external">sevoflurane</a>, <a class="drug drug_general" data-topicid="8891" href="/d/drug information/8891.html" rel="external">desflurane</a>, <a class="drug drug_general" data-topicid="8992" href="/d/drug information/8992.html" rel="external">isoflurane</a>, halothane) include ease of titration, dose-dependent decreases in skeletal muscle tone, cerebral metabolic rate, and bronchodilation (except desflurane), and ability to use end-tidal anesthetic concentration (ETAC) values to titrate anesthetic depth. ETAC values of 0.8 to 1 MAC are typically adequate to prevent awareness with recall.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Disadvantages</strong> – General disadvantages include dose-dependent systemic vasodilation (with decreased blood pressure) and respiratory depression, and increased risk of postoperative nausea and vomiting (PONV) compared with most IV anesthetic alternatives, unless prophylactic antiemetics are administered. The volatile inhalation anesthetics also have the potential to precipitate malignant hyperthermia. (See <a class="local">'Volatile inhalation agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrous oxide</strong> – <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> (N<sub>2</sub>O) is a pressurized anesthetic gas delivered via a flow meter on the anesthesia machine. We routinely use N<sub>2</sub>O unless there is a contraindication. Advantages include rapid onset and offset of anesthetic effect that allows decreased dosing of other anesthetic agents, as well as analgesia and anxiolysis. N<sub>2</sub>O is always avoided in patients with pre-existing bowel distention, increased middle ear pressure, pneumothorax, pneumoperitoneum, pneumocephalus, intraocular gas, or venous air embolism. (See <a class="local">'Nitrous oxide gas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total intravenous anesthesia (TIVA)</strong> – TIVA employs an IV sedative-hypnotic anesthetic (typically <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>) and an analgesic agent (typically an opioid). (See <a class="local">'Total intravenous anesthesia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Propofol</strong> – <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">Propofol</a> is most commonly selected as the sedative-hypnotic component of a TIVA technique because of its rapid onset and recovery; beneficial antiemetic, bronchodilatory, and anticonvulsant properties; and relatively benign adverse side effects  (<a class="graphic graphic_table graphicRef102350" href="/d/graphic/102350.html" rel="external">table 8</a>). Propofol is infused at 75 to 150 mcg/kg per minute, with titration according to individual requirements, the degree of noxious surgical stimulation, and coadministration of other anesthetic agents. (See <a class="local">'Sedative-hypnotic agent: Propofol'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids</strong> – An opioid is most commonly employed as the analgesic component of a TIVA technique. Potential adverse effects include exacerbation of hypotensive effects of <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a>, respiratory depression, bradycardia, PONV, ileus, constipation, delirium, pruritus, and potential for acute tolerance. Choice of a specific opioid is dependent upon patient- and procedure-specific factors  (<a class="graphic graphic_table graphicRef111779" href="/d/graphic/111779.html" rel="external">table 6</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other adjuvant agents</strong> – Infusions of other IV agents (eg, <a class="drug drug_general" data-topicid="8897" href="/d/drug information/8897.html" rel="external">dexmedetomidine</a>, <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>) may be used for patient-specific or procedure-specific reasons to reduce or replace <a class="drug drug_general" data-topicid="9826" href="/d/drug information/9826.html" rel="external">propofol</a> as the sedative-hypnotic component or an opioid as the analgesic component of a TIVA technique. Overall, these adjunct agents have limited benefits and specific potential adverse effects, as noted above. (See <a class="local">'Adjuvant agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular blocking agents (NMBAs)</strong> – A nondepolarizing NMBA is typically employed if profound muscle relaxation in the surgical field and/or absence of movement are necessary  (<a class="graphic graphic_table graphicRef114271" href="/d/graphic/114271.html" rel="external">table 7</a>). Disadvantages of neuromuscular blockade include intraoperative elimination of purposeful movement as a sign of awareness, and the potential for residual postoperative neuromuscular weakness, which may lead to respiratory complications. (See <a class="local">'Neuromuscular blocking agents'</a> above.)</p><p></p><p class="headingAnchor" id="H3079622807"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Liza M Weavind, MBBCh, FCCM, MMHC and Adam King, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aldecoa C, Bettelli G, Bilotta F, et al. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. Eur J Anaesthesiol 2017; 34:192.</a></li><li><a class="nounderline abstract_t">Berger M, Schenning KJ, Brown CH 4th, et al. Best Practices for Postoperative Brain Health: Recommendations From the Fifth International Perioperative Neurotoxicity Working Group. Anesth Analg 2018; 127:1406.</a></li><li><a class="nounderline abstract_t">American Society of Anesthesiologists Task Force on Intraoperative Awareness. Practice advisory for intraoperative awareness and brain function monitoring: a report by the american society of anesthesiologists task force on intraoperative awareness. Anesthesiology 2006; 104:847.</a></li><li><a class="nounderline abstract_t">Zorrilla-Vaca A, Healy RJ, Wu CL, Grant MC. Relation between bispectral index measurements of anesthetic depth and postoperative mortality: a meta-analysis of observational studies. Can J Anaesth 2017; 64:597.</a></li><li><a class="nounderline abstract_t">Kertai MD, White WD, Gan TJ. Cumulative duration of "triple low" state of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia is not associated with increased mortality. Anesthesiology 2014; 121:18.</a></li><li><a class="nounderline abstract_t">Sessler DI, Sigl JC, Kelley SD, et al. Hospital stay and mortality are increased in patients having a "triple low" of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia. Anesthesiology 2012; 116:1195.</a></li><li><a class="nounderline abstract_t">Short TG, Campbell D, Frampton C, et al. Anaesthetic depth and complications after major surgery: an international, randomised controlled trial. Lancet 2019; 394:1907.</a></li><li><a class="nounderline abstract_t">O'Bryan LJ, Atkins KJ, Lipszyc A, et al. Inflammatory Biomarker Levels After Propofol or Sevoflurane Anesthesia: A Meta-analysis. Anesth Analg 2022; 134:69.</a></li><li><a class="nounderline abstract_t">Hendrickx JF, Eger EI 2nd, Sonner JM, Shafer SL. Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 2008; 107:494.</a></li><li><a class="nounderline abstract_t">van den Berg JP, Vereecke HE, Proost JH, et al. Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. Br J Anaesth 2017; 118:44.</a></li><li><a class="nounderline abstract_t">Brown EN, Pavone KJ, Naranjo M. Multimodal General Anesthesia: Theory and Practice. Anesth Analg 2018; 127:1246.</a></li><li><a class="nounderline abstract_t">Fawcett WJ, Jones CN. Bespoke intra-operative anaesthesia - the end of the formulaic approach? Anaesthesia 2018; 73:1062.</a></li><li><a class="nounderline abstract_t">Egan TD. Are opioids indispensable for general anaesthesia? Br J Anaesth 2019; 122:e127.</a></li><li><a class="nounderline abstract_t">Torri G. Inhalation anesthetics: a review. Minerva Anestesiol 2010; 76:215.</a></li><li><a class="nounderline abstract_t">Kuizenga MH, Colin PJ, Reyntjens KMEM, et al. Population Pharmacodynamics of Propofol and Sevoflurane in Healthy Volunteers Using a Clinical Score and the Patient State Index: A Crossover Study. Anesthesiology 2019; 131:1223.</a></li><li><a class="nounderline abstract_t">Jakobsson J. Desflurane: a clinical update of a third-generation inhaled anaesthetic. Acta Anaesthesiol Scand 2012; 56:420.</a></li><li><a class="nounderline abstract_t">Dexter F, Bayman EO, Epstein RH. Statistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane. Anesth Analg 2010; 110:570.</a></li><li><a class="nounderline abstract_t">McKay RE, Malhotra A, Cakmakkaya OS, et al. Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane. Br J Anaesth 2010; 104:175.</a></li><li><a class="nounderline abstract_t">Buhre W, Disma N, Hendrickx J, et al. European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice. Br J Anaesth 2019; 122:587.</a></li><li><a class="nounderline abstract_t">Sun R, Jia WQ, Zhang P, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. Cochrane Database Syst Rev 2015; :CD008984.</a></li><li><a class="nounderline abstract_t">Miller TE, Gan TJ. Total intravenous anesthesia and anesthetic outcomes. J Cardiothorac Vasc Anesth 2015; 29 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Nimmo AF, Absalom AR, Bagshaw O, et al. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia. Anaesthesia 2019; 74:211.</a></li><li><a class="nounderline abstract_t">Pasin L, Nardelli P, Pintaudi M, et al. Closed-Loop Delivery Systems Versus Manually Controlled Administration of Total IV Anesthesia: A Meta-analysis of Randomized Clinical Trials. Anesth Analg 2017; 124:456.</a></li><li><a class="nounderline abstract_t">Ohtani N, Kida K, Shoji K, et al. Recovery profiles from dexmedetomidine as a general anesthetic adjuvant in patients undergoing lower abdominal surgery. Anesth Analg 2008; 107:1871.</a></li><li><a class="nounderline abstract_t">Dolk A, Cannerfelt R, Anderson RE, Jakobsson J. Inhalation anaesthesia is cost-effective for ambulatory surgery: a clinical comparison with propofol during elective knee arthroscopy. Eur J Anaesthesiol 2002; 19:88.</a></li><li><a class="nounderline abstract_t">Kumar G, Stendall C, Mistry R, et al. A comparison of total intravenous anaesthesia using propofol with sevoflurane or desflurane in ambulatory surgery: systematic review and meta-analysis. Anaesthesia 2014; 69:1138.</a></li><li><a class="nounderline abstract_t">Kuizenga MH, Vereecke HE, Struys MM. Model-based drug administration: current status of target-controlled infusion and closed-loop control. Curr Opin Anaesthesiol 2016; 29:475.</a></li><li><a class="nounderline abstract_t">Irwin MG, Chung CKE, Ip KY, Wiles MD. Influence of propofol-based total intravenous anaesthesia on peri-operative outcome measures: a narrative review. Anaesthesia 2020; 75 Suppl 1:e90.</a></li><li><a class="nounderline abstract_t">Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs 2010; 13:929.</a></li><li><a class="nounderline abstract_t">Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012; 115:274.</a></li><li><a class="nounderline abstract_t">Kim KM. Remimazolam: pharmacological characteristics and clinical applications in anesthesiology. Anesth Pain Med (Seoul) 2022; 17:1.</a></li><li><a class="nounderline abstract_t">Doi M, Morita K, Takeda J, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth 2020; 34:543.</a></li><li><a class="nounderline abstract_t">Cinotti R. An update on remimazolam and anaphylaxis. Eur J Anaesthesiol 2023; 40:153.</a></li><li><a class="nounderline abstract_t">Hasushita Y, Nagao M, Miyazawa Y, et al. Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report. A A Pract 2022; 16:e01616.</a></li><li><a class="nounderline abstract_t">Kim KM, Lee H, Bang JY, et al. Anaphylaxis following remimazolam administration during induction of anaesthesia. Br J Anaesth 2022; 129:e122.</a></li><li><a class="nounderline abstract_t">Veyckemans F. Opioid-free anaesthesia: Still a debate? Eur J Anaesthesiol 2019; 36:245.</a></li><li><a class="nounderline abstract_t">Lirk P, Rathmell JP. Opioid-free anaesthesia: Con: it is too early to adopt opioid-free anaesthesia today. Eur J Anaesthesiol 2019; 36:250.</a></li><li><a class="nounderline abstract_t">Mauermann E, Ruppen W, Bandschapp O. Different protocols used today to achieve total opioid-free general anesthesia without locoregional blocks. Best Pract Res Clin Anaesthesiol 2017; 31:533.</a></li><li><a class="nounderline abstract_t">Wu CL, King AB, Geiger TM, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Opioid Minimization in Opioid-Naïve Patients. Anesth Analg 2019; 129:567.</a></li><li><a class="nounderline abstract_t">Kent ML, Hurley RW, Oderda GM, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health Care System Initiatives. Anesth Analg 2019; 129:543.</a></li><li><a class="nounderline abstract_t">Elkassabany NM, Mariano ER. Opioid-free anaesthesia - what would Inigo Montoya say? Anaesthesia 2019; 74:560.</a></li><li><a class="nounderline abstract_t">Soffin EM, Lee BH, Kumar KK, Wu CL. The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. Br J Anaesth 2019; 122:e198.</a></li><li><a class="nounderline abstract_t">Lavand'homme P. Opioid-free anaesthesia: Pro: damned if you don't use opioids during surgery. Eur J Anaesthesiol 2019; 36:247.</a></li><li><a class="nounderline abstract_t">Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet 2017; 56:893.</a></li><li><a class="nounderline abstract_t">Xu B, Li Z, Zhou D, et al. The Influence of Age on Sensitivity to Dexmedetomidine Sedation During Spinal Anesthesia in Lower Limb Orthopedic Surgery. Anesth Analg 2017; 125:1907.</a></li><li><a class="nounderline abstract_t">Dutta S, Lal R, Karol MD, et al. Influence of cardiac output on dexmedetomidine pharmacokinetics. J Pharm Sci 2000; 89:519.</a></li><li><a class="nounderline abstract_t">Rolle A, Paredes S, Cortínez LI, et al. Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. Br J Anaesth 2018; 120:969.</a></li><li><a class="nounderline abstract_t">Piao G, Wu J. Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials. Arch Med Sci 2014; 10:19.</a></li><li><a class="nounderline abstract_t">Chabot-Doré AJ, Schuster DJ, Stone LS, Wilcox GL. Analgesic synergy between opioid and α2 -adrenoceptors. Br J Pharmacol 2015; 172:388.</a></li><li><a class="nounderline abstract_t">Bielka K, Kuchyn I, Babych V, et al. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic сholecystectomy: a randomized controlled study. BMC Anesthesiol 2018; 18:44.</a></li><li><a class="nounderline abstract_t">Wu Z, Yu J, Lin Q, et al. Effects of an Intraoperative Intravenous Bolus Dose of Dexmedetomidine on Remifentanil-Induced Postinfusion Hyperalgesia in Patients Undergoing Thyroidectomy: A Double-Blind Randomized Controlled Trial. Anesth Analg 2021; 132:320.</a></li><li><a class="nounderline abstract_t">Dutta A, Sethi N, Sood J, et al. The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study. Anesth Analg 2019; 129:84.</a></li><li><a class="nounderline abstract_t">Jessen Lundorf L, Korvenius Nedergaard H, Møller AM. Perioperative dexmedetomidine for acute pain after abdominal surgery in adults. Cochrane Database Syst Rev 2016; 2:CD010358.</a></li><li><a class="nounderline abstract_t">Naik BI, Nemergut EC, Kazemi A, et al. The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery. Anesth Analg 2016; 122:1646.</a></li><li><a class="nounderline abstract_t">Tang C, Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J Pain Res 2017; 10:1899.</a></li><li><a class="nounderline abstract_t">Miao M, Xu Y, Li B, et al. Intravenous administration of dexmedetomidine and quality of recovery after elective surgery in adult patients: A meta-analysis of randomized controlled trials. J Clin Anesth 2020; 65:109849.</a></li><li><a class="nounderline abstract_t">Aouad MT, Zeeni C, Al Nawwar R, et al. Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study. Anesth Analg 2017.</a></li><li><a class="nounderline abstract_t">Kim SY, Kim JM, Lee JH, et al. Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth 2013; 111:222.</a></li><li><a class="nounderline abstract_t">Kim DJ, Kim SH, So KY, Jung KT. Effects of dexmedetomidine on smooth emergence from anaesthesia in elderly patients undergoing orthopaedic surgery. BMC Anesthesiol 2015; 15:139.</a></li><li><a class="nounderline abstract_t">Duan X, Coburn M, Rossaint R, et al. Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials. Br J Anaesth 2018; 121:384.</a></li><li><a class="nounderline abstract_t">Beloeil H, Garot M, Lebuffe G, et al. Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery. Anesthesiology 2021; 134:541.</a></li><li><a class="nounderline abstract_t">Singh A, Brenna CTA, Broad J, et al. The Effects of Dexmedetomidine on Perioperative Neurocognitive Outcomes After Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Ann Surg 2022; 275:864.</a></li><li><a class="nounderline abstract_t">Colin PJ, Hannivoort LN, Eleveld DJ, et al. Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. Br J Anaesth 2017; 119:211.</a></li><li><a class="nounderline abstract_t">Edokpolo LU, Mastriano DJ, Serafin J, et al. Discharge Readiness after Propofol with or without Dexmedetomidine for Colonoscopy: A Randomized Controlled Trial. Anesthesiology 2019; 131:279.</a></li><li><a class="nounderline abstract_t">Demiri M, Antunes T, Fletcher D, Martinez V. Perioperative adverse events attributed to α2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis. Br J Anaesth 2019; 123:795.</a></li><li><a class="nounderline abstract_t">Aouad MT, Zeeni C, Al Nawwar R, et al. Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study. Anesth Analg 2019; 129:1504.</a></li><li><a class="nounderline abstract_t">Sleigh JW, Vacas S, Flexman AM, Talke PO. Electroencephalographic Arousal Patterns Under Dexmedetomidine Sedation. Anesth Analg 2018; 127:951.</a></li><li><a class="nounderline abstract_t">Corssen G, Domino EF. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29.</a></li><li><a class="nounderline abstract_t">Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018; 43:456.</a></li><li><a class="nounderline abstract_t">Schubert A, Licina MG, Lineberry PJ. The effect of ketamine on human somatosensory evoked potentials and its modification by nitrous oxide. Anesthesiology 1990; 72:33.</a></li><li><a class="nounderline abstract_t">Kano T, Shimoji K. The effects of ketamine and neuroleptanalgesia on the evoked electrospinogram and electromyogram in man. Anesthesiology 1974; 40:241.</a></li><li><a class="nounderline abstract_t">Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial. Lancet 2017; 390:267.</a></li><li><a class="nounderline abstract_t">Dunn LK, Durieux ME. Another Win for Lidocaine, Another Loss for Magnesium? Anesth Analg 2018; 127:591.</a></li><li><a class="nounderline abstract_t">Dunn LK, Durieux ME. Perioperative Use of Intravenous Lidocaine. Anesthesiology 2017; 126:729.</a></li><li><a class="nounderline abstract_t">Carabalona JF, Delwarde B, Duclos A, et al. Serum Concentrations of Lidocaine During Bariatric Surgery. Anesth Analg 2020; 130:e5.</a></li><li><a class="nounderline abstract_t">Kim MH, Kim MS, Lee JH, et al. Intravenously Administered Lidocaine and Magnesium During Thyroid Surgery in Female Patients for Better Quality of Recovery After Anesthesia. Anesth Analg 2018; 127:635.</a></li><li><a class="nounderline abstract_t">Weibel S, Jelting Y, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev 2018; 6:CD009642.</a></li><li><a class="nounderline abstract_t">Weinberg GL. Perioperative Lidocaine Infusion: Does the Risk Outweigh the Benefit? Anesth Analg 2021; 132:906.</a></li><li><a class="nounderline abstract_t">Hamed MA. Comparative Study between Magnesium Sulfate and Lidocaine for Controlled Hypotension during Functional Endoscopic Sinus Surgery: A Randomized Controlled Study. Anesth Essays Res 2018; 12:715.</a></li><li><a class="nounderline abstract_t">Omar AM. Can systemic lidocaine be used in controlled hypotension? double-blinded randomized controlled study in patients undergoing functional endoscopic sinus surgery. Egyptian Journal of Anaesthesia 2013; 29:295.</a></li><li><a class="nounderline abstract_t">Checketts MR, Alladi R, Ferguson K, et al. Recommendations for standards of monitoring during anaesthesia and recovery 2015: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia 2016; 71:85.</a></li><li><a class="nounderline abstract_t">McLean DJ, Diaz-Gil D, Farhan HN, et al. Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications. Anesthesiology 2015; 122:1201.</a></li><li><a class="nounderline abstract_t">McGrath CD, Hunter JM. Monitoring of neuromuscular block. Contin Educ Anaesth Crit Care Pain 2006; 6:7.</a></li></ol></div><div id="topicVersionRevision">Topic 96308 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28187050" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Best Practices for Postoperative Brain Health: Recommendations From the Fifth International Perioperative Neurotoxicity Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571982" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Practice advisory for intraoperative awareness and brain function monitoring: a report by the american society of anesthesiologists task force on intraoperative awareness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28361391" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Relation between bispectral index measurements of anesthetic depth and postoperative mortality: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24936920" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cumulative duration of "triple low" state of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia is not associated with increased mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22546967" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hospital stay and mortality are increased in patients having a "triple low" of low blood pressure, low bispectral index, and low minimum alveolar concentration of volatile anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31645286" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaesthetic depth and complications after major surgery: an international, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34908547" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Inflammatory Biomarker Levels After Propofol or Sevoflurane Anesthesia: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633028" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28039241" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30252709" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multimodal General Anesthesia: Theory and Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29533468" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Bespoke intra-operative anaesthesia - the end of the formulaic approach?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31104756" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Are opioids indispensable for general anaesthesia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inhalation anesthetics: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31567365" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Population Pharmacodynamics of Propofol and Sevoflurane in Healthy Volunteers Using a Clinical Score and the Patient State Index: A Crossover Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188283" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Desflurane: a clinical update of a third-generation inhaled anaesthetic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820242" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Statistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20037150" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of increased body mass index and anaesthetic duration on recovery of protective airway reflexes after sevoflurane vs desflurane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30916011" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : European Society of Anaesthesiology Task Force on Nitrous Oxide: a narrative review of its role in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545294" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025040" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Total intravenous anesthesia and anesthetic outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30378102" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Guidelines for the safe practice of total intravenous anaesthesia (TIVA): Joint Guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099320" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Closed-Loop Delivery Systems Versus Manually Controlled Administration of Total IV Anesthesia: A Meta-analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020132" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recovery profiles from dexmedetomidine as a general anesthetic adjuvant in patients undergoing lower abdominal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11999607" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inhalation anaesthesia is cost-effective for ambulatory surgery: a clinical comparison with propofol during elective knee arthroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24847783" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A comparison of total intravenous anaesthesia using propofol with sevoflurane or desflurane in ambulatory surgery: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152471" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Model-based drug administration: current status of target-controlled infusion and closed-loop control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31903578" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Influence of propofol-based total intravenous anaesthesia on peri-operative outcome measures: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154153" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190555" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35139608" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32417976" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36722186" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An update on remimazolam and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36149988" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36055819" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anaphylaxis following remimazolam administration during induction of anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817358" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Opioid-free anaesthesia: Still a debate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817360" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Opioid-free anaesthesia: Con: it is too early to adopt opioid-free anaesthesia today.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29739542" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Different protocols used today to achieve total opioid-free general anesthesia without locoregional blocks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31082966" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on Perioperative Opioid Minimization in Opioid-Naïve Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30897590" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health Care System Initiatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30802930" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Opioid-free anaesthesia - what would Inigo Montoya say?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30915988" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30817359" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Opioid-free anaesthesia: Pro: damned if you don't use opioids during surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28105598" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991112" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Influence of Age on Sensitivity to Dexmedetomidine Sedation During Spinal Anesthesia in Lower Limb Orthopedic Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737913" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Influence of cardiac output on dexmedetomidine pharmacokinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661414" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24701209" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Systematic assessment of dexmedetomidine as an anesthetic agent: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24641506" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Analgesic synergy between opioid andα2 -adrenoceptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678158" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dexmedetomidine infusion as an analgesic adjuvant during laparoscopicсholecystectomy: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639389" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of an Intraoperative Intravenous Bolus Dose of Dexmedetomidine on Remifentanil-Induced Postinfusion Hyperalgesia in Patients Undergoing Thyroidectomy: A Double-Blind Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29787410" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889627" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Perioperative dexmedetomidine for acute pain after abdominal surgery in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27003917" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Effect of Dexmedetomidine on Postoperative Opioid Consumption and Pain After Major Spine Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28860845" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32403055" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intravenous administration of dexmedetomidine and quality of recovery after elective surgery in adult patients: A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29293178" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23524149" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446479" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of dexmedetomidine on smooth emergence from anaesthesia in elderly patients undergoing orthopaedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032877" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630043" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35543164" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Effects of Dexmedetomidine on Perioperative Neurocognitive Outcomes After Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854543" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31233409" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discharge Readiness after Propofol with or without Dexmedetomidine for Colonoscopy: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31623842" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Perioperative adverse events attributed toα2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743169" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29933272" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Electroencephalographic Arousal Patterns Under Dexmedetomidine Sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5325977" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29870457" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297131" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effect of ketamine on human somatosensory evoked potentials and its modification by nitrous oxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4814246" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The effects of ketamine and neuroleptanalgesia on the evoked electrospinogram and electromyogram in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576285" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30113972" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Another Win for Lidocaine, Another Loss for Magnesium?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28114177" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Perioperative Use of Intravenous Lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30399021" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Serum Concentrations of Lidocaine During Bariatric Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29324495" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intravenously Administered Lidocaine and Magnesium During Thyroid Surgery in Female Patients for Better Quality of Recovery After Anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29864216" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33438966" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Perioperative Lidocaine Infusion: Does the Risk Outweigh the Benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30283182" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparative Study between Magnesium Sulfate and Lidocaine for Controlled Hypotension during Functional Endoscopic Sinus Surgery: A Randomized Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Can systemic lidocaine be used in controlled hypotension? double-blinded randomized controlled study in patients undergoing functional endoscopic sinus surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26582586" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Recommendations for standards of monitoring during anaesthesia and recovery 2015: Association of Anaesthetists of Great Britain and Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25919486" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Monitoring of neuromuscular block</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
